Glucocorticoid-induced osteoporosis: presentation and comments on the new American College of Rheumatology guidelines

The article presents a review of the clinical guidelines of 2017 American College of Rheumatology for prevention and treatment of glucocorticoid-induced osteoporosis. The guidelines i contain fracture risk gradation not only for people over 40 years , based on the measurement of bone mineral density...

Full description

Bibliographic Details
Main Author: Natalia V. Toroptsova
Format: Article
Language:English
Published: Endocrinology Research Centre 2018-04-01
Series:Остеопороз и остеопатии
Subjects:
Online Access:https://osteo-endojournals.ru/osteo/article/viewFile/9593/7199
id doaj-1391861d09ad4653a940b705b1b93c95
record_format Article
spelling doaj-1391861d09ad4653a940b705b1b93c952021-07-02T21:14:58ZengEndocrinology Research CentreОстеопороз и остеопатии2072-26802311-07162018-04-0120311412010.14341/osteo20173114-1208452Glucocorticoid-induced osteoporosis: presentation and comments on the new American College of Rheumatology guidelinesNatalia V. Toroptsova0Research Institute of Rheumatology named after V.A. NasonovaThe article presents a review of the clinical guidelines of 2017 American College of Rheumatology for prevention and treatment of glucocorticoid-induced osteoporosis. The guidelines i contain fracture risk gradation not only for people over 40 years , based on the measurement of bone mineral density, 10-year probability of fractures by FRAX and prior osteoporotic fractures, but also for people under 40 years. The guidelines present , recommendations for initial and follow-up treatment for prevention of glucocorticoid-induced osteoporosis according the level of risk of fractures in different age groups of adults, and in children from 4 years of age, in patients with organ transplant and patients older than 30 years, receiving very high-dose of glucocorticoids . Oral bisphosphonates were recommended as first line treatment due to safety, cost, and because of lack of evidence for superior antifracture benefits from other OP medications. Oral bisohosphonates could be switched to another medication in case of intolerance. The issues of applicability of these recommendations in national clinical practice are being discussed.https://osteo-endojournals.ru/osteo/article/viewFile/9593/7199osteoporosisglucocorticoidfracturepractice guidelinecomment
collection DOAJ
language English
format Article
sources DOAJ
author Natalia V. Toroptsova
spellingShingle Natalia V. Toroptsova
Glucocorticoid-induced osteoporosis: presentation and comments on the new American College of Rheumatology guidelines
Остеопороз и остеопатии
osteoporosis
glucocorticoid
fracture
practice guideline
comment
author_facet Natalia V. Toroptsova
author_sort Natalia V. Toroptsova
title Glucocorticoid-induced osteoporosis: presentation and comments on the new American College of Rheumatology guidelines
title_short Glucocorticoid-induced osteoporosis: presentation and comments on the new American College of Rheumatology guidelines
title_full Glucocorticoid-induced osteoporosis: presentation and comments on the new American College of Rheumatology guidelines
title_fullStr Glucocorticoid-induced osteoporosis: presentation and comments on the new American College of Rheumatology guidelines
title_full_unstemmed Glucocorticoid-induced osteoporosis: presentation and comments on the new American College of Rheumatology guidelines
title_sort glucocorticoid-induced osteoporosis: presentation and comments on the new american college of rheumatology guidelines
publisher Endocrinology Research Centre
series Остеопороз и остеопатии
issn 2072-2680
2311-0716
publishDate 2018-04-01
description The article presents a review of the clinical guidelines of 2017 American College of Rheumatology for prevention and treatment of glucocorticoid-induced osteoporosis. The guidelines i contain fracture risk gradation not only for people over 40 years , based on the measurement of bone mineral density, 10-year probability of fractures by FRAX and prior osteoporotic fractures, but also for people under 40 years. The guidelines present , recommendations for initial and follow-up treatment for prevention of glucocorticoid-induced osteoporosis according the level of risk of fractures in different age groups of adults, and in children from 4 years of age, in patients with organ transplant and patients older than 30 years, receiving very high-dose of glucocorticoids . Oral bisphosphonates were recommended as first line treatment due to safety, cost, and because of lack of evidence for superior antifracture benefits from other OP medications. Oral bisohosphonates could be switched to another medication in case of intolerance. The issues of applicability of these recommendations in national clinical practice are being discussed.
topic osteoporosis
glucocorticoid
fracture
practice guideline
comment
url https://osteo-endojournals.ru/osteo/article/viewFile/9593/7199
work_keys_str_mv AT nataliavtoroptsova glucocorticoidinducedosteoporosispresentationandcommentsonthenewamericancollegeofrheumatologyguidelines
_version_ 1721322239405588480